Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

EpiCblood

financed

Closed

Towards early cancer detection and tumor classification using epigenomic biomark...

Towards early cancer detection and tumor classification using epigenomic biomarkers in blood Early cancer detection could increase curative treatment and long-term survival. Dying cells release small DNA fragments wrapped around a core of histone proteins into the bloodstream, so-called circulating cell-free nucleosomes (... see more

31/12/2028

LMU MUENCHEN

1M€

Project Budget: 1M€

Project leader

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2023-11-27

ERC-2023-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

LMU MUENCHEN

1.50M€ | Leader

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 61 months Date Start: 2023-11-27
End date: 2028-12-31

Project leader

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 1M€

participation deadline Sin fecha límite de participación.

Project description Early cancer detection could increase curative treatment and long-term survival. Dying cells release small DNA fragments wrapped around a core of histone proteins into the bloodstream, so-called circulating cell-free nucleosomes (cf-nucleosomes). They carry DNA sequence information and histone modifications stable in blood, reflecting promising epigenomic disease biomarkers. But, the low proportion of cf-nucleosomes originating from cancerous cells versus the large background of nucleosomes arising from dying blood cells poses significant challenges for early cancer detection using circulating cf-nucleosomes. In EpiCblood, I will tackle these challenges and propose two complementary strategies to increase the number of cancer-signature cf-nucleosomes for cancer detection and tumor classification. In the first strategy, I will employ my previously developed synthetic histone modification readers to profile abundant histone modifications on cf-nucleosomes allowing me to seize up to 35 percent of the human genome non-invasively. I will prove this technology’s concept by detecting earlier stages of pancreatic cancer and simultaneously classifying molecular tumor subtypes. Furthermore, I hypothesize that tumorigenesis gives rise to cancer-specific genomic sites decorated with combinatorial histone marks, so-called bivalent regions, found explicitly in cancer and not in healthy adult cell types. In the second strategy, I will employ a computational pipeline to map cancer-specific bivalent sites across multiple cancer genomes. I will use my well-established combinatorial histone mark readers to test their diagnostic potential as cancer-specific biomarkers in blood plasma from healthy donors and cancer patients. My genomics expertise and proven technology provide an excellent basis for accomplishing the planned goals. EpiCblood will be a major step towards developing precise and rich liquid biopsy assays for multiple clinical applications in cancer management.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers